|
Trasylol
Heart Surgery | Kidney Failure | Heart Failure | Heart Attacks
Trasylol, also known as aprotinin, has been in use worldwide since the 1990s to reduce bleeding related to heart bypass surgery (CABG).
Based on the latest data, it appears that over four and a half million people had been given the drug Trasylol, and over a million were in the United States. Trasylol is made by Bayer AG.
TRASYLOL: When is it used?
Trasylol is used during open heart surgery, heart bypass, heart valve replacement and other cardiac surgery to control bleeding.
TRASYLOL: What do leading medical journals say?
A major study recently published in the New England Journal of Medicine found that Trasylol significantly raised the risk of death compared to competing products and that patients given Trasylol had a more than 50 percent higher death rate than patients who were given alternative, cheaper blood clotting drugs.
TRASYLOL: What does the FDA say?
The FDA, pressured Bayer AG to suspend sales of Trasylol in November 2007. The FDA, stated that access to the drug will be limited to investigational use for certain patients who have no acceptable alternatives but supports the removal of Trasylol from regular use.
It appears that the patients who received Trasylol were more likely to die than compared to patients who received an alternative drug.
The patients who were given Trasylol and died after surgery, usually died of kidney failure, heart failure, heart attacks and/or strokes.
For more on trasylol cases, please follow this link.
Please navigate to the links below to find more information on a variety of topics and what you can do to protect your legal rights or contact us.
|
